XRTX Rasio cepet XORTX Therapeutics Inc.

The XORTX Therapeutics Inc. (XRTX) price chart demonstrates the asset's dynamics, with its current metric standing at 3.58. The business is currently focused on testing kidney treatments, relying on grant funding in the absence of stable profits. Growth potential is driven by proprietary molecules and the outsourcing of production for nephrologists. The efficiency of discovering new formulas is being enhanced through the implementation of robotic analysis in immunological research.

The ratio is calculated by dividing the sum of cash and accounts receivable by current liabilities, completely ignoring inventories. This metric determines the issuer's ability to instantaneously settle debts without liquidating inventory. For XORTX Therapeutics Inc. (XRTX), which holds patents in kidney therapy, this confirms financial autonomy during R&D development. The trend of the average quick ratio demonstrates a balance between operational stability and capital efficiency.